Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma
Athanasios Niotis1, Sofianiki Mastronikoli2, Despoina Spyropoulou3
1Department of Breast Surgery, "Henry Dunant" Medical Hospital, Athens, Greece.
Introduction:
Breast adenocarcinoma (BAC) is a leading cause of cancer-dependent morbidity and mortality in females worldwide. Concerning critical genes that are implicated in its onset and progression in BAC, the tumor suppressor protein Tp53 (gene locus: 17p13.1) and its negative regulator the Mouse Double Minute 2 Homolog (MDM2) - an oncogene (gene locus: 12q14.3) - form a significant feedback loop.
Objective:
The aim of the current molecular review was to investigate the MDM2 oncogene deregulation mechanisms in BAC and the corresponding targeted therapeutic approaches.
Material And Method:
A set of fifty (n=50) published papers in the international database of PubMed was selected based on the new exposed knowledge in the field of mdm2 gene and protein normal function and deregulation. They also focused on the anti-mdm2 targeted regimens in BAC. The following keywords were used: breast, cancer, oncogene, mdm2, targeted therapies.
Results:
Mdm2 oncogene amplification - combined or not with specific gene polymorphisms - is a crucial molecular event in BAC onset and progression. These genetic alterations negatively affect the Tp53-MDM2 balance and cell homeostasis in breast epithelia.
Conclusions:
MDM2 oncogene overexpression - due predominantly to amplification - is a relatively frequent event in BAC. Understanding the impact of mdm2 on genetic substrate and biological behavior of BAC, many study groups have experimentally explored the role of specific anti-mdm2 agents and suggested a fragment of them for targeting its oncogenic activity in BACs characterized by specific genetic signatures.
Insights
MDM2 oncogene amplification drives breast adenocarcinoma (BAC) progression by disrupting the Tp53-MDM2 balance. Targeted therapies against MDM2 show promise for specific BAC genetic profiles.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast adenocarcinoma (BAC) is a major cause of cancer mortality in women globally.
- The tumor suppressor p53 and its negative regulator, the MDM2 oncogene, form a critical feedback loop in BAC.
- Deregulation of this loop is implicated in BAC development and progression.
Purpose of the Study:
- To investigate MDM2 oncogene deregulation mechanisms in BAC.
- To review targeted therapeutic strategies for MDM2-driven BAC.
Main Methods:
- A systematic review of 50 PubMed-indexed studies.
- Keywords included: breast, cancer, oncogene, MDM2, targeted therapies.
- Focus on MDM2 gene/protein function, deregulation, and anti-MDM2 regimens in BAC.
Main Results:
- MDM2 oncogene amplification, with or without gene polymorphisms, is a key event in BAC onset and progression.
- These genetic alterations disrupt the Tp53-MDM2 balance and breast epithelial cell homeostasis.
- MDM2 overexpression, primarily due to amplification, is frequent in BAC.
Conclusions:
- Understanding MDM2's role is crucial for developing targeted therapies in BAC.
- Specific anti-MDM2 agents are being explored for BACs with distinct genetic signatures.
- Targeting MDM2 offers a promising therapeutic avenue for specific BAC subtypes.
Related Concept Videos
02:23Abnormal Proliferation
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...